Turner & Co. (Glasgow) leads new entries to Lentitek cap table

Lentitek Ltd is an Edinburgh-based biotechnology company founded in 2019. The firm develops proprietary technology to enhance the quality and yield of lentiviral vectors used in advanced gene and cell therapies. Its platform is offered to asset developers through a serviced CRO license model to improve manufacturing and accessibility.

A recent confirmation statement (period ending 3 July 2026) shows Turner & Co. (Glasgow) Limited has joined the cap table with 1,865 ordinary shares. This investor also holds stakes in Neurotherapeutics Ltd, Mocean Energy Ltd, and Biotangents Limited. Old College Capital Holdings Limited entered the cap table with 1,696 shares, while Edinburgh Technology Fund exited with the same amount. Old College Capital Holdings Limited is also a shareholder in Resolution Therapeutics Limited and Sofant Technologies Ltd.

Orchard Venture Capital Limited joined with 892 shares, replacing Orchard Capital Ventures which exited the cap table with an identical holding. Orchard Venture Capital Limited also backs Sofant Technologies Ltd. Barwell PLC is another new entrant with 282 shares. Barwell PLC is a shareholder in Enterobiotix Limited. These multiple entries may signal a recent round of investment. Shancastle Investments Limited remains on the cap table with 938 shares.